A5042751028- Atherosclerosis and Cardiovascular Diseases
- Lipoproteins and Cardiovascular Health
- Protein Degradation and Inhibitors
- Cancer, Lipids, and Metabolism
- Histone Deacetylase Inhibitors Research
- Immune cells in cancer
- Adipokines, Inflammation, and Metabolic Diseases
- Antiplatelet Therapy and Cardiovascular Diseases
- Cerebrovascular and Carotid Artery Diseases
- Dupuytren's Contracture and Treatments
- Nail Diseases and Treatments
- Angiogenesis and VEGF in Cancer
- Autoimmune Bullous Skin Diseases
- HIV Research and Treatment
- MRI in cancer diagnosis
- Phagocytosis and Immune Regulation
- Single-cell and spatial transcriptomics
- Protease and Inhibitor Mechanisms
- Epigenetics and DNA Methylation
- Nanoplatforms for cancer theranostics
- Obstructive Sleep Apnea Research
- Surgical Sutures and Adhesives
- Diabetes Treatment and Management
- Neuroscience of respiration and sleep
- Traumatic Brain Injury and Neurovascular Disturbances
Amsterdam University Medical Centers
2020-2025
University of Amsterdam
2020-2024
University of Oxford
2020-2021
Resverlogix (Canada)
2020
Amsterdam UMC Location University of Amsterdam
2020
Oxidized phospholipids play a key role in the atherogenic potential of lipoprotein(a) (Lp[a]); however, Lp(a) is complex particle that warrants research into additional proinflammatory mediators. We hypothesized Lp(a)-associated lipids contribute to atherogenicity Lp(a).
Elevated lipoprotein(a) [Lp(a)] is strongly associated with an increased cardiovascular disease (CVD) risk. We previously reported that pro-inflammatory activation of circulating monocytes a potential mechanism by which Lp(a) mediates CVD. Since potent Lp(a)-lowering therapies are emerging, it interest whether patients elevated experience beneficial anti-inflammatory effects following large reductions in Lp(a).Using transcriptome analysis, we show healthy individuals Lp(a), as well CVD...
Systemic low-grade inflammation, measured by plasma high-sensitivity C-reactive protein (hsCRP) levels, is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). To date, however, it unknown whether hsCRP associated with adverse histological plaque features.
Abstract Background Patients with cardiovascular disease (CVD) and type 2 diabetes (DM2) have a high residual risk for experiencing major adverse cardiac event. Dysregulation of epigenetic mechanisms gene transcription in innate immune cells contributes to CVD development but is currently not targeted by therapies. Apabetalone (RVX-208) small molecule inhibitor bromodomain extra-terminal (BET) proteins—histone acetylation readers that drive pro-inflammatory pro-atherosclerotic transcription....
The endothelium is a crucial regulator of vascular homeostasis by controlling barrier integrity as well acting an important signal transducer, thereby illustrating that endothelial cells are not inert cells. In the context atherosclerosis, this function impaired and become activated, resulting in upregulation adhesion molecules, secretion cytokines chemokines internalization integrins. Finally, leads to increased vessel permeability, facilitating leukocyte extravasation fostering...
General population studies have shown that elevated Lp(a) (lipoprotein[a]) levels are an emerging risk factor for cardiovascular disease and subsequent events. The role of the secondary MACE in patients undergoing carotid endarterectomy (CEA) is unknown. Our objective to assess association with CEA.Lp(a) concentrations were determined preoperative blood samples 944 consecutive CEA included Athero-Express Biobank Study. During 3-year follow-up, major adverse events (MACE), consisting...
Abstract Dupuytren’s Disease (DD) is a common fibroproliferative disease of the palmar fascia. We previously identified strong association with non-synonymous variant (rs1042704, pD273N) in MMP14 (encoding MT1-MMP). investigated functional consequences this variant, and demonstrated that MT1-MMP (MT1-N 273 ) exhibits only 17% cell surface collagenolytic activity compared to ancestral enzyme (MT1-D ). Cells expressing both MT1-D MT1-N 1:1 ratio, mimicking heterozygous state, possess 38% cells...
Introduction: Hyperactivation of the monocyte inflammatory response is partly controlled by epigenetic mechanisms and contributes to atherosclerotic plaque formation in patients with cardiovascular disease (CVD) type 2 diabetes mellitus (DM2). Hypothesis: Monocyte activation DM2+CVD regulated bromodomain extraterminal (BET) readers can be inhibited apabetalone - a clinical stage BET inhibitor. Methods: CD14+ monocytes from 14 12 matched control subjects were treated ex vivo 25 μM ± U/mL...